Faris El Refaie
President & General Manager, Pharmaceuticals, GSK Canada
Faris was appointed to the role of President & General Manager of GSK Canada in August 2020 and is responsible for all pharmaceutical operations for GSK in Canada. He currently Chairs the Canadian Country Executive Board representing the Pharmaceutical business and is a prominent member of the Pharmaceutical Leadership Team.
Prior to joining GSK, Faris was the Global Commercial VP leading the Lynparza & DNA Damage Response Franchise for AstraZeneca, and lead of the Biosimilars development and commercialization program, globally.
Since August 2020, Faris has led GSK’s response to the COVID-19 pandemic in Canada, partnering with governments and health system providers to ensure that Canadian’s access to innovative medical countermeasures, including early-stage treatments, is among the best in the world. Faris is a Member of the Board for Innovative Medicines Canada, as well as Montréal InVivo – two leading organizations that work to grow and promote Canada’s life sciences industry.
As an enterprise leader, Faris is committed to fostering a diverse and inclusive workplace and is working to increase representation among underrepresented groups of people across GSK’s workforce.
Faris studied at McMaster University in Hamilton, Ontario, Canada, where he obtained two degrees, an Honours Bachelor of Science in Biochemistry and a Master of Business Administration in Marketing and Operations.